Keywords: cell, therapeutics, buys, zevalin, biogen, idec, 10m
Cell Therapeutics buys Zevalin from Biogen Idec for $10M, with up to $20M extra plus milestones
Article | 03 September 2007
Cell Therapeutics has agreed to acquire Zevalin (ibritumomab tiuxetan), the first US-approved radioimmunotherapy, from fellow USA-based drugmaker Biogen Idec. CT ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Is failure to adopt business process management putting the pharma industry at risk?
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
